Resultados globales: 14 registros encontrados en 0.02 segundos.
Artículos, Encontrados 11 registros
Documentos de investigación, Encontrados 3 registros
Artículos Encontrados 11 registros  1 - 10siguiente  ir al registro:
1.
11 p, 1.8 MB The long journey to bring a Myc inhibitor to the clinic / Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Whitfield and Soucek discuss decades of research and a vast array of strategies that are finally yielding clinical trials for Myc inhibitors in cancer. The oncogene Myc is deregulated in the majority of human tumors and drives numerous hallmarks of cancer. [...]
2021 - 10.1083/jcb.202103090
The Journal of Cell Biology, Vol. 220 (june 2021)  
2.
27 p, 2.3 MB Structural and biophysical insights into the function of the intrinsically disordered Myc oncoprotein / Beaulieu, Marie-Eve (Peptomyc S.L.) ; Castillo, Francisco (Peptomyc S.L.) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Myc is a transcription factor driving growth and proliferation of cells and involved in the majority of human tumors. Despite a huge body of literature on this critical oncogene, our understanding of the exact molecular determinants and mechanisms that underlie its function is still surprisingly limited. [...]
2020 - 10.3390/cells9041038
Cells, Vol. 9, Issue 4 (April 2020) , art. 1038  
3.
19 p, 1.3 MB Blocking Myc to treat cancer : reflecting on two decades of Omomyc / Massó-Vallés, Daniel (Peptomyc S.L.) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. [...]
2020 - 10.3390/cells9040883
Cells, Vol. 9, Issue 4 (April 2020) , art. 883  
4.
10 p, 3.3 MB The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets / Zacarías-Fluck, Mariano F. (Vall d'Hebron Institut d'Oncologia) ; Jauset, Toni (Hospital Universitari Vall d'Hebron) ; Martínez-Martín, Sandra (Vall d'Hebron Institut d'Oncologia) ; Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ; Casacuberta-Serra, Sílvia (Hospital Universitari Vall d'Hebron) ; Massó-Vallés, Daniel (Vall d'Hebron Institut d'Oncologia) ; Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ; Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ; González-Larreategui, Íñigo (Vall d'Hebron Institut d'Oncologia) ; López-Estévez, Sergio (Hospital Universitari Vall d'Hebron) ; Brown-Swigart, Lamorna (Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California) ; Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ; Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Madan, Babita (Program in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School) ; Virshup, David M. (Program in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School) ; Evan, Gerard I (Department of Biochemistry, University of Cambridge) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Zacarías-Fluck, et al identify and validate the Wnt receptor Fzd9 as a key effector of Myc-Wnt signaling cross-talk in a mouse model of Myc-driven pancreatic insulinomas. The huge cadre of genes regulated by Myc has obstructed the identification of critical effectors that are essential for Myc-driven tumorigenesis. [...]
2021 - 10.26508/lsa.201900490
Life Science Alliance, Vol. 4 (march 2021)  
5.
986.5 KB Finding MYCure / Beaulieu, Marie-Eve (Peptomyc S.L.) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. [...]
2019 - 10.1080/23723556.2019.1618178
Molecular & cellular oncology, Vol. 6, Num. 5 (June 2019) , art. e1618178  
6.
9 p, 3.4 MB Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies / Pesarrodona Roches, Mireia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Jauset, Toni (Vall d'Hebron Institut d'Oncologia) ; Díaz Riascos, Zamira Vanessa (Centro de Investigación Biomédica en Red) ; Sánchez Chardi, Alejandro (Universitat de Barcelona. Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals) ; Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ; Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Sánchez García, Laura (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Baltà Foix, Ricardo. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Mancilla, Sandra (Centro de Investigación Biomédica en Red) ; Fernández Caparrós, Yolanda (Centro de Investigación Biomédica en Red) ; Rinas, Ursula (Leibniz University of Hannover. Helmholtz Centre for Infection Research) ; Schwartz, Simó (Centro de Investigación Biomédica en Red) ; Soucek, Laura (Vall d'Hebron Institut d'Oncologia) ; Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Abasolo, Ibane (Centro de Investigación Biomédica en Red) ; Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44 tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. [...]
2019 - 10.1002/advs.201900849
Advanced science, Vol. 6, issue 18 (Sep. 2019) , art. 1900849  
7.
13 p, 5.3 MB BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC / Jauset, Toni (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Massó Vallés, Daniel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Martínez Martín, Sandra (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ; Foradada, Laia (Vall d'Hebron Institut d'Oncologia) ; Fiorentino, Francesco Paolo (Department of Biomedical Sciences, University of Sassari) ; Yokota, Jun (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Haendler, Bernard (Drug Discovery, Bayer AG) ; Siegel, Stephan (Drug Discovery, Bayer AG) ; Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Effectively treating KRAS-driven tumors remains an unsolved challenge. The inhibition of downstream signaling effectors is a way of overcoming the issue of direct targeting of mutant KRAS, which has shown limited efficacy so far. [...]
2018 - 10.18632/oncotarget.24648
Oncotarget, Vol. 9 (april 2018) , p. 18734-18746  
8.
13 p, 1.2 MB Strategies to Inhibit Myc and Their Clinical Applicability / Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Beaulieu, Marie-Eve (Hospital Universitari Vall d'Hebron) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Myc is an oncogene deregulated in most-perhaps all-human cancers. Each Myc family member, c-, L-, and N-Myc, has been connected to tumor progression and maintenance. Myc is recognized as a "most wanted" target for cancer therapy, but has for many years been considered undruggable, mainly due to its nuclear localization, lack of a defined ligand binding site, and physiological function essential to the maintenance of normal tissues. [...]
2017 - 10.3389/fcell.2017.00010
Frontiers in Cell and Developmental Biology, Vol. 5 (February 2017) , art. 10  
9.
2 p, 193.7 KB Ibrutinib repurposing : from B-cell malignancies to solid tumors / Massó Vallés, Daniel (Vall d'Hebron Institut d'Oncologia) ; Jauset, Toni (Vall d'Hebron Institut d'Oncologia) ; Soucek, Laura (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
Ibrutinib (Imbruvica®, also known as PCI-32765) is a first-in-class, irreversible small-molecule inhibitorof Bruton's Tyrosine Kinase (BTK) that binds covalently to cysteine C481 within the ATP-binding pocket. [...]
2016 - 10.18632/oncoscience.310
Oncoscience, Vol. 3, Num. 5-6 (may 2016) , p. 147-148  
10.
15 p, 7.1 MB Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation / Fiorentino, Francesco Paolo (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Tokgün, Elvan (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Solé-Sánchez, Sònia (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Giampaolo, Sabrina (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Tokgün, Onur (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Jauset, Toni (Vall d'Hebron Institut d'Oncologia) ; Kohno, Takashi (National Cancer Center Research Institute (Tòquio, Japó)) ; Perucho, Manuel (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Yokota, Jun (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer)
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer with high mortality. One of the MYC family genes, MYC, MYCL or MYCN, is amplified in ~20% of the SCLCs; therefore, MYC proteins are potential therapeutic targets in SCLC patients. [...]
2016 - 10.18632/oncotarget.8826
Oncotarget, Vol. 7, Num. 21 (May 2016) , p. 31014-31028  

Artículos : Encontrados 11 registros   1 - 10siguiente  ir al registro:
Documentos de investigación Encontrados 3 registros  
1.
149 p, 7.4 MB Targeting MYC in B-cell haematologic malignancies / Martínez-Martín, Sandra ; Soucek, Laura, dir. ; Arribas, Joaquín V. (Vicente), dir.
La importància de la funció de MYC en el càncer (i l'origen del nom de la oncoproteïna) es va descobrir a finals dels 70, amb la identificació de la seqüència del retrovirus aviar causant de la leucèmia mielocítica. [...]
La importancia de la función de MYC en el cáncer (y el origen del nombre de la oncoproteína) se descubrió a finales de los años 70, con la identificación de la secuencia del retrovirus aviar causante de la leucemia mielocítica. [...]
The importance of MYC function in cancer (and the origin of the oncoprotein's name) was discovered in the late '70s when the sequence of the avian retrovirus that causes myelocytic leukaemia was identified. [...]

2020  
2.
150 p, 5.1 MB Inhibiting Myc in cancer using Omomyc : from defining the fundamental mechanism of action to its pharmacological application / Jauset González, Toni ; Soucek, Laura, dir. ; Lizcano de Vega, José Miguel, dir. ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
Identifying and targeting cancer cell components that play non-degenerate and non-redundant functions within cancers could lead to the development of more effective therapies. Myc is considered a prime example of such a target, and has been characterized as a downstream effector of multiple oncogenic pathways. [...]
[Bellaterra] : Universitat Autònoma de Barcelona, 2018.  
3.
168 p, 6.5 MB Inhibiting Myc and the Myc dependent inflammatory response as cancer therapies / Massó Vallés, Daniel ; Soucek, Laura, dir. ; Arribas, Joaquín V., , dir. (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
Aquesta tesi s'ha realitzat al Laboratori de Modelització de Teràpies Anti-tumorals en Ratolí dirigit per la Dra. Laura Soucek al Programa de Recerca Preclínica del Vall d'Hebron Institut d'Oncologia (VHIO), i comprèn dos projectes diferenciats centrats en dues de les funcions oncogèniques de Myc. [...]
The work of this thesis was carried out in the Mouse Models of Cancer Therapies Laboratory led by Dr. Laura Soucek in the Preclinical Research Program of the Vall d'Hebron Institute of Oncology (VHIO), and comprises two differentiated parts centered on two oncogenic functions of Myc. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2017.  

Vea también: autores con nombres similares
1 Soucek, L.
3 Soucek, Laura,
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.